Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18156316 | 0.92 | PTGER1 (0.38) | ALDH1A1RAB9APTGER1PTGER4PTGER3 | |
| SCHEMBL18182044 | 0.91 | ACLY (0.34) | MAPK14ALDH1A1MAPTPTGER1MRGPRX4 | |
| SCHEMBL18182574 | 0.91 | ACLY (0.34) | MAPK14ALDH1A1MAPTPTGER1MRGPRX4 | |
| SCHEMBL18182642 | 0.91 | PTGER1 (0.38) | RAB9APTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL18182021 | 0.91 | PTGER1 (0.38) | MAPK14ALDH1A1POLBRAB9AMAPT | |
| SCHEMBL18178568 | 0.90 | PTGER1 (0.38) | MAPK14ALDH1A1POLBRAB9AMAPT | |
| SCHEMBL18182931 | 0.90 | ALDH1A1 (0.39) | MAPK14ALDH1A1POLBRAB9AMAPT | |
| SCHEMBL18182029 | 0.90 | ALDH1A1 (0.39) | ALDH1A1POLBRAB9AMAPTPTGER1 | |
| SCHEMBL18156240 | 0.90 | MRGPRX4 (0.40) | ALDH1A1POLBRAB9AMAPTPTGER1 | |
| SCHEMBL18156164 | 0.90 | ALDH1A1 (0.39) | ALDH1A1POLBRAB9AMAPTPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | MAPK14 2775/4885ALDH1A1 3176/4885POLB 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.